Vibalogics establishes US presence with virotherapy facility in Boston
The specialist CDMO's $150 million 3-year investment plan will provide a complete suite of virotherapy services to support drug developers and their most "revolutionary" products.
Vibalogics, a global contract development and manufacturing organization (CDMO), announced last Wednesday that it has initiated Phase I of its planned $150 million investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The 3-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150 million across redevelopment, equipment and personnel.
The CDMO, which specializes in manufacturing oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.
The facility will be equipped with state-of the-art technology and enable a significant capacity increase, including 2000-L scale bioreactors and additional fill-finish capabilities.
According to Vibalogics’ CEO, Tom Hochuli, the site will provide a complete suite of virotherapy services to support drug developers and their most "revolutionary" products.
He said: "The addition of a late-stage clinical and commercial facility means we can easily tech transfer our customers’ products from our early-phase manufacturing facility in Germany to the US, resulting in a complete end-to-end service from pre-clinical to commercial supply."
The facility is expected to create 100 jobs initially, reaching 250 employees during the next 4 years.
For the past 15 years, Vibalogics has specialized in the manufacturing of oncolytic viruses, viral vector vaccines and viral vectors offering process development, manufacturing, testing and fill-finish services for early phase clinical trials.
Stefan Beyer, President and Managing Director of Vibalogics GmbH said: “The decision to expand stems from high demand for biomanufacturing services and development capacity in viral vector vaccines and oncolytic viruses and is an important step in integrating our future late-phase and commercial operations into our business.”
The company was recently selected by Janssen Pharmaceutical Companies, a Johnson & Johnson company, as one of its manufacturing partners for its investigational COVID-19 vaccine candidate.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance